| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| Activité liée au VIH dans 24 sites hospitaliers de France métropolitaine en 1995-1996 |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
1 |
| An analysis of behaviour, health, and GDP during the Covid-19 pandemic in Europe |
0 |
0 |
2 |
2 |
0 |
12 |
22 |
22 |
| Anxiety Increases The Willingness To Be Exposed To Covid-19 Risk Among Young Adults In France |
0 |
0 |
0 |
6 |
0 |
0 |
2 |
32 |
| Anxiety Increases the Willingness the Willingness to Be Exposed to Covid-19 Risk among Young Adults in France |
0 |
0 |
0 |
8 |
0 |
0 |
0 |
16 |
| Anxiety Increases the Willingness the Willingness to Be Exposed to Covid-19 Risk among Young Adults in France |
0 |
0 |
0 |
2 |
0 |
0 |
2 |
18 |
| Anxiety increases the willingness to be exposed to covid-19 risk among young adults in France |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
5 |
| Anxiety increases the willingness to be exposed to covid-19 risk among young adults in France |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
9 |
| Associations between anxiety and the willingness to be exposed to COVID-19 risk among French young adults during the first pandemic wave |
0 |
0 |
0 |
4 |
0 |
0 |
2 |
4 |
| Associations between anxiety and the willingness to be exposed to COVID-19 risk among French young adults during the first pandemic wave |
0 |
0 |
0 |
3 |
0 |
1 |
2 |
4 |
| Assurance maladie en Suisse: l'assurance supplémentaire nuit-elle à la concurrence sur l'assurance de base ? |
0 |
0 |
0 |
28 |
0 |
0 |
0 |
234 |
| Assurance maladie en Suisse: l'assurance supplémentaire nuit-elle à la concurrence sur l'assurance de base ? |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
9 |
| Assurance maladie en Suisse: l'assurance supplémentaire nuit-elle à la concurrence sur l'assurance de base ? |
0 |
0 |
0 |
1 |
0 |
0 |
2 |
44 |
| Assurance maladie en Suisse: les assurances supplémentaires nuisent-elles à la concurrence sur l'assurance de base ? |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
13 |
| Assurance maladie en Suisse: les assurances supplémentaires nuisent-elles à la concurrence sur l'assurance de base ? |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
16 |
| Assurance maladie: la gestion du risque long |
0 |
0 |
0 |
0 |
0 |
1 |
5 |
1,000 |
| Cannabis: comment reprendre le contrôle ? |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
22 |
| Cannabis: comment reprendre le contrôle ? |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
8 |
| Changing time and emotions |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
3 |
| Changing time and emotions |
0 |
0 |
0 |
10 |
0 |
0 |
0 |
43 |
| Changing time and emotions |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
9 |
| Changing time and emotions |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
11 |
| Child health and access to health care in France: Evidence on the role of family income |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
7 |
| Child health and access to health care in France: Evidence on the role of family income |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
5 |
| Child health and use of health care services in France: Evidence on the role of family income |
0 |
0 |
0 |
19 |
0 |
0 |
4 |
21 |
| Child health and use of health care services in France: Evidence on the role of family income |
0 |
0 |
1 |
40 |
1 |
1 |
5 |
69 |
| Comment analyser le fonctionnement des systèmes de santé ? |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
14 |
| Comment lutter contre les inégalités de santé ? |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
18 |
| Comment meurt une épidémie ? La fin du sida en débat |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
24 |
| Comment meurt une épidémie ? La fin du sida en débat |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
14 |
| Comportements sexuels risques et incitations: l'impact des nouveaux traitements sur la prevention du VIH |
0 |
0 |
0 |
42 |
0 |
0 |
2 |
676 |
| Concurrence en santé: marché des soins, marché de l'assurance |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
| Concurrence en santé: marché des soins, marché de l'assurance |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
11 |
| Cost-effectiveness analysis of early access to medical and social care for migrants living with HIV in France |
0 |
0 |
0 |
10 |
0 |
0 |
0 |
29 |
| Cost-effectiveness analysis of early access to medical and social care for migrants living with HIV in France |
0 |
0 |
0 |
9 |
0 |
0 |
1 |
5 |
| Data MArkets and OPtimal Sample Size Determination |
0 |
0 |
0 |
0 |
1 |
1 |
3 |
2,835 |
| Decomposition of Bivariate Inequality Indicesby Attributes |
0 |
0 |
0 |
56 |
0 |
2 |
3 |
197 |
| Decomposition of bivariate inequality indices by attributes |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
17 |
| Decomposition of bivariate inequality indices by attributes |
0 |
0 |
0 |
12 |
0 |
0 |
0 |
69 |
| Decomposition of bivariate inequality indices by attributes |
0 |
0 |
0 |
0 |
0 |
2 |
3 |
32 |
| Decomposition of bivariate inequality indices by attributes |
0 |
0 |
1 |
2 |
0 |
1 |
3 |
12 |
| Discouting and Optimizing Capital Accumulation as a Variational Minmax Problem |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
280 |
| Disease Eradication: Private vs. Public Vaccination |
0 |
0 |
0 |
0 |
1 |
2 |
3 |
568 |
| Dépenses de santé: l'hypothèse d'aléa moral |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
623 |
| Economic and public health consequences of delayed access to medical care for migrants living with HIV in France |
0 |
0 |
0 |
0 |
0 |
1 |
3 |
13 |
| Economic and public health consequences of delayed access to medical care for migrants living with HIV in France |
0 |
0 |
0 |
0 |
1 |
1 |
3 |
35 |
| End-Of-Life Medical Spending In Last Twelve Months Of Life Is Lower Than Previously Reported |
0 |
0 |
0 |
1 |
0 |
0 |
4 |
26 |
| End-Of-Life Medical Spending In Last Twelve Months Of Life Is Lower Than Previously Reported |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
80 |
| Family income and child health in the UK |
0 |
0 |
0 |
3 |
0 |
0 |
2 |
25 |
| Family income and child health in the UK |
0 |
0 |
1 |
40 |
0 |
0 |
3 |
96 |
| Family income and child health in the UK |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
14 |
| Family income and child health in the UK |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
15 |
| Gérer le risque de dépendance |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
| Gérer le risque de dépendance |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
21 |
| Incentive and Selection Effects in Health Insurance |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
28 |
| L'économie du reste à charge |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
| L'économie du reste à charge |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
15 |
| L'équité dans le financement du système d'indemnisation: quelques éléments de réflexion, beaucoup d'incertitudes |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
11 |
| La concurrence, c'est l'innovation ? |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
6 |
| La concurrence, c'est l'innovation ? |
0 |
0 |
0 |
0 |
0 |
1 |
2 |
22 |
| La demande de prévention est-elle induite par l'offre ? |
0 |
0 |
0 |
0 |
1 |
1 |
4 |
16 |
| La demande de prévention est-elle induite par l'offre ? |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
8 |
| La demande de prévention est-elle induite par l'offre ? |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
17 |
| La lancinante réforme de l'assurance maladie |
0 |
0 |
0 |
0 |
0 |
1 |
7 |
51 |
| La réception d'une note du Conseil d'Analyse Économique relative à la légalisation du cannabis |
0 |
0 |
1 |
1 |
0 |
0 |
1 |
1 |
| La réception d'une note du Conseil d'Analyse Économique relative à la légalisation du cannabis |
0 |
0 |
1 |
2 |
0 |
0 |
2 |
4 |
| La régulation des dépenses de santé: comment faire ? |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
11 |
| La régulation des dépenses de santé: comment faire ? |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
8 |
| La régulation des secteurs de la santé: volume 6 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
8 |
| La régulation des secteurs de la santé: volume 6 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
25 |
| La régulation des secteurs de la santé: volume 6 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
| La santé par quels moyens et à quels prix ? |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
30 |
| La santé par quels moyens et à quels prix ? |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
| La santé, par quels moyens et à quels prix ? |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
7 |
| La santé, par quels moyens et à quels prix ? |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
8 |
| Le gradient et la transmission intergénérationnelle de la santé pendant l'enfance |
0 |
0 |
0 |
3 |
0 |
1 |
2 |
38 |
| Le gradient et la transmission intergénérationnelle de la santé pendant l'enfance |
0 |
0 |
0 |
1 |
0 |
0 |
2 |
12 |
| Le gradient et la transmission intergénérationnelle de la santé pendant l'enfance |
0 |
0 |
0 |
1 |
0 |
0 |
2 |
17 |
| Le gradient et la transmission intergénérationnelle de la santé pendant l'enfance |
0 |
0 |
0 |
1 |
0 |
1 |
2 |
22 |
| L’AMO ne suffit plus à garantir un accès aux soins sans barrière financière |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
16 |
| L’AMO ne suffit plus à garantir un accès aux soins sans barrière financière |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
12 |
| Measuring Well Being Inequality |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
4 |
| Measuring Well Being Inequality |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
10 |
| Medical Spending in France: Concentration, Persistence and Evolution before Death |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
25 |
| Medical Spending in France: Concentration, Persistence and Evolution before Death |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
8 |
| Moral Hazard and the Demand for Physician Services: First Lessons from a French Natural Experiment |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2,155 |
| Parents' education and child body weight in France: The trajectory of the gradient in the early years |
0 |
0 |
0 |
22 |
0 |
1 |
9 |
87 |
| Parents' education and child body weight in France: The trajectory of the gradient in the early years |
0 |
0 |
0 |
27 |
0 |
0 |
3 |
13 |
| Parents' education and child body weight in France: The trajectory of the gradient in the early years |
0 |
0 |
0 |
20 |
0 |
0 |
1 |
69 |
| Parents’ education and child body weight in France: The trajectory of the gradient in the early years |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
19 |
| Parents’ education and child body weight in France: The trajectory of the gradient in the early years |
0 |
0 |
0 |
0 |
0 |
1 |
3 |
14 |
| Peut-on evaluer le cout d'une maladie? |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
273 |
| Politique de santé et inégalités sociales |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
| Politique de santé et inégalités sociales |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
19 |
| Politiques de santé en Europe et inégalités sociales |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
13 |
| Politiques de santé et inégalités sociales en Europe |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
12 |
| Pour un système de santé plus efficace |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
22 |
| Pour un système de santé plus efficace |
0 |
0 |
0 |
31 |
0 |
1 |
3 |
88 |
| Pricing and R&D with Related Margins |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
562 |
| Quelle assurance contre le risque dépendance ? |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
8 |
| Quelle assurance contre le risque dépendance ? |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
| Quelles formes de concurrence en assurance santé ? |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
28 |
| Quelles sont les perspectives ouvertes par l’exploitation des données administratives ? |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
6 |
| Quelles sont les perspectives ouvertes par l’exploitation des données administratives ? |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
13 |
| Rational Epidemics and their Public Control |
0 |
0 |
0 |
0 |
0 |
1 |
7 |
631 |
| Refonder l'assurance-maladie |
0 |
0 |
0 |
10 |
0 |
0 |
2 |
48 |
| Refonder l’assurance-maladie |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
23 |
| Refonder l’assurance-maladie |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
7 |
| Reforming Incentive Schemes Under Political Constraints: The Physician Agency |
0 |
0 |
0 |
103 |
0 |
0 |
0 |
406 |
| Reforming incentive schemes under political constraints: The physician agency |
0 |
0 |
0 |
91 |
0 |
0 |
0 |
300 |
| Reforming incentive schemes under political constraints: The physician agency |
0 |
0 |
0 |
5 |
1 |
1 |
1 |
56 |
| Reforming incentive schemes under political contraints: The physician agency |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
17 |
| Réformer le système de remboursement pour les soins de ville, une analyse par microsimulation |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
14 |
| Réformer le système de remboursement pour les soins de ville, une analyse par microsimulation |
0 |
0 |
0 |
0 |
0 |
1 |
2 |
10 |
| Santé: l'heure des choix |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
30 |
| Santé: l'heure des choix |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
11 |
| Scared by Foreigners and their Products? Survey Evidence from France |
0 |
0 |
0 |
68 |
0 |
0 |
0 |
355 |
| Separating Selection and Incentive Effects in Health Insurance |
0 |
0 |
1 |
143 |
0 |
0 |
1 |
430 |
| Separating Selection and Incentive Effects: an Econometric Study of Swiss Health Insurance Claims Data |
0 |
0 |
0 |
314 |
0 |
0 |
2 |
1,074 |
| Separating Selection and Incentive Effects: an Econometric Study of Swiss Health Insurance Claims Data |
0 |
0 |
0 |
0 |
1 |
2 |
4 |
48 |
| Separating selection and incentive effects in health insurance |
0 |
0 |
1 |
7 |
0 |
0 |
1 |
32 |
| Separating selection and incentive effects in health insurance |
0 |
0 |
1 |
30 |
0 |
1 |
4 |
122 |
| Socio-economic Inequalities in access to Covid-19 tests in France in 2020: Evidence from the EPICOV socio-epidemiological cohort |
0 |
0 |
1 |
1 |
0 |
0 |
4 |
4 |
| Socio-economic Inequalities in access to Covid-19 tests in France in 2020: Evidence from the EPICOV socio-epidemiological cohort |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
3 |
| Socio-economic inequalities in access to COVID-19 tests in France in 2020: evidence from the EPICOV socio-epidemiological cohort |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Sunspot Fluctuations around a Steady State: The Case of Multidimensional One-Step forward Looking Economic Models |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
378 |
| The Transmission of Information through Prices: an Alternative Exploratory Assessment of Market Performance |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
246 |
| The influence of supplementary health insurance on switching behaviour: evidence from Swiss data |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
5 |
| The influence of supplementary health insurance on switching behaviour: evidence from Swiss data |
0 |
0 |
0 |
0 |
0 |
3 |
4 |
38 |
| The influence of supplementary health insurance on switching behaviour: evidence on Swiss data |
0 |
0 |
0 |
12 |
1 |
1 |
2 |
153 |
| The influence of supplementary health insurance on switching behaviour: evidence on Swiss data |
0 |
0 |
0 |
2 |
0 |
0 |
2 |
32 |
| The subjective value of a life with Down syndrome: Evidence from amniocentesis decision |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
15 |
| The subjective value of a life with Down syndrome: Evidence from amniocentesis decision |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
6 |
| The subjective value of a life with Down syndrome: Evidence from amnocentesis decision |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
8 |
| The subjective value of a life with Down syndrome: Evidence from amnocentesis decision |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
| The subjective value of a life with Down syndrome: Evidence from amnocentesis decision |
0 |
0 |
0 |
2 |
1 |
1 |
3 |
11 |
| Therapeutic non adherence: A rational behavior revealing patient preferences? |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
46 |
| Therapeutic non adherence: A rational behavior revealing patient preferences? |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
7 |
| Therapeutic non adherence: a rational behavior revealing patient preferences ? |
0 |
0 |
0 |
4 |
0 |
0 |
3 |
37 |
| Therapeutic non adherence: a rational behavior revealing patient preferences ? |
0 |
0 |
0 |
23 |
0 |
0 |
2 |
162 |
| Workplace smoking ban effects in an heterogeneous smoking population |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
20 |
| Workplace smoking ban effects in an heterogeneous smoking population |
0 |
0 |
0 |
47 |
0 |
0 |
1 |
134 |
| Workplace smoking ban effects on unhappy smokers |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
43 |
| Workplace smoking ban effects on unhappy smokers |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
6 |
| À quoi peut servir la concurrence en assurance santé ? |
0 |
0 |
0 |
10 |
0 |
0 |
0 |
53 |
| Total Working Papers |
0 |
0 |
11 |
1,283 |
12 |
48 |
237 |
16,259 |
LogEc is hosted by the
Örebro University School of Business.